Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark

Rhea-AI Summary

Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland. Mater Private is described as Ireland's largest electrophysiology center, performing over 1,000 EP procedures annually. The company said LockeT was rapidly adopted during onboarding, with 52 staff trained in two days, and that a European key opinion leader helped introduce the device. The agreement represents an initial commercial expansion into an eighth European country following CE mark receipt and supports the company's international adoption strategy.

News Market Reaction – VTAK

+0.91%

6 alerts

+0.91% Session close to close

-7.8% Trough in 2 hr 16 min

$3.44M Market Cap

1.3x Rel. Volume

In the Dec 18 session, VTAK gained 0.91%, reflecting a mild positive market reaction. Argus tracked a trough of -7.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued international expansion of LockeT, adding Ireland’s largest e...

Analysis

This announcement highlights continued international expansion of LockeT, adding Ireland’s largest electrophysiology center, which performs over 1,000 procedures annually, as a multi‑year customer. It builds on recent launches in Switzerland, South Africa and a VIVO tender in Hungary, reinforcing a consistent commercialization theme. Investors may focus on how broader adoption at high‑volume centers translates into revenue against the backdrop of prior filings that noted small sales, significant losses and going concern risks.

Key Figures

Annual EP procedures: over 1,000 procedures Staff trained: 52 staff members Training duration: two days +1 more

4 metrics

Annual EP procedures over 1,000 procedures Mater Private Hospital EP center volume

Staff trained 52 staff members LockeT onboarding at Mater Private Hospital

Training duration two days Time to train 52 staff on LockeT

European expansion eighth European country LockeT footprint in Europe since CE Mark

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	VIVO tender win	Positive	+13.3%	Multi-year VIVO tender in Hungary, first installation in Central/Eastern Europe.
Dec 01	LockeT Swiss launch	Positive	-3.3%	Commercial launch of LockeT in Switzerland with distribution via FuMedica AG.
Nov 25	Reimbursement change	Positive	+12.1%	CMS adds EP ablation codes to ASC list, framed as LockeT opportunity.
Nov 20	LockeT South Africa	Positive	-9.9%	Rapid LockeT uptake in five South African hospitals with repeat orders.
Nov 13	Q3 2025 earnings	Negative	-10.9%	Revenue growth but substantial losses and going concern warning disclosed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Commercial and reimbursement wins for LockeT and VIVO have produced mixed reactions, with some strong rallies but also notable selloffs on positive news.

Recent Company History

Over the last months, Catheter Precision reported Q3 2025 results showing revenue of $226,000 (up 135%) but ongoing losses and a going concern warning. Since then, news has focused on international expansion of LockeT and VIVO: rapid LockeT uptake in South Africa, a reimbursement-driven opportunity in U.S. ambulatory surgery centers effective January 1, 2026, a LockeT launch in Switzerland with over 10,000 units shipped globally, and a multi‑year VIVO tender in Hungary. Today’s Ireland expansion further extends this international rollout theme.

Key Terms

electrophysiology, arrhythmia, suture retention device

3 terms

electrophysiology medical

"Ireland’s largest electrophysiology center"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

arrhythmia medical

"a key institution for arrhythmia treatment and innovation"

An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.

suture retention device medical

"the commercial launch of its LockeT suture retention device in Switzerland"

A suture retention device is a small medical tool used during wound closure to hold stitches in place and spread the force of the stitch over a larger area of skin or tissue, similar to how a button or washer prevents a rope from cutting through fabric. For investors, these devices matter because they can reduce wound complications, shorten surgery or recovery time, and lower follow-up costs—factors that affect hospital adoption, reimbursement, and market demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology center

Fort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (VTAK - NYSE/American), a leader in advanced electrophysiology solutions, today announced the successful implementation of LockeT and the first LockeT purchase order at Mater Private Hospital, located in Dublin, Ireland. This marks a significant milestone in the company’s global expansion strategy and reinforces its commitment to improving procedural safety and efficiency in cardiac care.

Mater Private Hospital is Ireland’s largest Electrophysiology (EP) center and performs over 1,000 EP procedures annually, making it a key institution for arrhythmia treatment and innovation.

Prof. Gábor Széplaki, a leading electrophysiologist and key opinion leader in Europe, has been instrumental in introducing LockeT to Mater Private Dublin. His commitment to innovation ensures LockeT will play a vital role in advancing EP care at the center by demonstrating the product’s ability to streamline workflows.

LockeT’s ease of use and rapid adoption were evident during onboarding, with the chief nurse personally training 52 staff members in just two days—a testament to the device’s intuitive design and operational efficiency.

Fatih Ayoglu, European Sales Manager at Catheter Precision, said, "Partnering with Mater Private Dublin is a major achievement for Catheter Precision. As Ireland’s largest EP center, their multi-annual commitment to LockeT validates our technology and strengthens our position in the global electrophysiology market. The acceptance of LockeT at this hospital further underscores Catheter Precision’s focus on expanding its footprint in international markets and driving adoption of technologies that improve clinical outcomes”.

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

# # #

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

FAQ

What did Catheter Precision (VTAK) announce on December 18, 2025 about LockeT in Ireland?

Catheter Precision announced the first LockeT purchase order and a multi‑year commitment from Mater Private Hospital in Dublin on Dec 18, 2025.

Why is the Mater Private Hospital order significant for VTAK investors?

Mater Private is described as Ireland's largest EP center with over 1,000 EP procedures annually, making the order a notable commercial foothold in Ireland.

How quickly was LockeT adopted at Mater Private Hospital according to Catheter Precision?

Catheter Precision reported that 52 staff were trained in two days, indicating rapid onboarding and usability.

Does the announcement state how much revenue the LockeT order will generate for VTAK?

No; the announcement confirms a purchase order and multi‑year commitment but does not disclose pricing or revenue figures.

How many European countries has LockeT expanded into after the CE mark according to the announcement?

The company said LockeT has expanded into an eighth European country following receipt of the CE mark.